By broadening definition of success to include sustained low-level HBsAg with suppressed HBV DNA, we can recognize clinically ...
AusperBio completes patient enrollment in phase III AUSHINE study of AHB-137 for chronic hepatitis B: San Francisco Tuesday, December 23, 2025, 15:00 Hrs [IST] AusperBio Therapeut ...
In September 2025, AusperBio completed participant enrolment in two Phase II studies evaluating AHB-137 for the functional cure of CHB. "AusperBio concludes enrolment in Phase III AUSHINE trial" was ...